Literature DB >> 10534475

Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: clinical trial methodology. Basel PAD Clinical Trial Methodology Group.

K H Labs1, J A Dormandy, K A Jaeger, C S Stuerzebecher, W R Hiatt.   

Abstract

Guidelines for the clinical development of drugs in peripheral arterial disease (PAD) have been issued by the Food and Drug Administration for the United States and by the regulatory agency of the European Union for Europe. With increasing globalization, transatlantic cooperation in drug research and development is essential for the future and would be substantially facilitated by the existence of transatlantic guidelines. A conference was held in Basel, Switzerland, in November 1997 to discuss the scientific background of the existing guidelines on the basis of published evidence and the extensive knowledge of clinical investigators and experienced regulators. The meeting was attended by 52 invited experts from the United States and Europe, as well as by representatives from the 2 regulatory authorities. The main conclusions from the meeting are presented and may serve as a reference for the future development of transatlantic guidelines for the evaluation of pharmacotherapy in PAD.

Entities:  

Mesh:

Year:  1999        PMID: 10534475     DOI: 10.1161/01.cir.100.17.e75

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

1.  Outcomes for clinical studies assessing drug and revascularization therapies for claudication and critical limb ischemia in peripheral artery disease.

Authors:  Scott Kinlay
Journal:  Circulation       Date:  2013-03-19       Impact factor: 29.690

2.  Multifactorial determinants of functional capacity in peripheral arterial disease: uncoupling of calf muscle perfusion and metabolism.

Authors:  Justin D Anderson; Frederick H Epstein; Craig H Meyer; Klaus D Hagspiel; Hongkun Wang; Stuart S Berr; Nancy L Harthun; Arthur Weltman; Joseph M Dimaria; Amy M West; Christopher M Kramer
Journal:  J Am Coll Cardiol       Date:  2009-08-11       Impact factor: 24.094

3.  Management of Critical Limb Ischemia.

Authors:  Scott Kinlay
Journal:  Circ Cardiovasc Interv       Date:  2016-02       Impact factor: 6.546

4.  Effect of type 2 diabetes mellitus on exercise intolerance and the physiological responses to exercise in peripheral arterial disease.

Authors:  S Green; C D Askew; P J Walker
Journal:  Diabetologia       Date:  2007-01-20       Impact factor: 10.122

5.  DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial.

Authors:  Yoshikazu Yonemitsu; Takuya Matsumoto; Hiroyuki Itoh; Jin Okazaki; Makiko Uchiyama; Kumi Yoshida; Mitsuho Onimaru; Toshihiro Onohara; Hiroyuki Inoguchi; Ryoichi Kyuragi; Mototsugu Shimokawa; Hiroshi Ban; Michiko Tanaka; Makoto Inoue; Tsugumine Shu; Mamoru Hasegawa; Yoichi Nakanishi; Yoshihiko Maehara
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

6.  Utility of Indocyanine Green Angiography in Arterial Selection during Free Flap Harvest in Patients with Severe Peripheral Vascular Disease.

Authors:  Anne K Maxwell; Frederic W-B Deleyiannis
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-10-25

7.  Liposome-based vascular endothelial growth factor-165 transfection with skeletal myoblast for treatment of ischaemic limb disease.

Authors:  Lei Ye; Husnain Kh Haider; Wahidah Bte Esa; Liping Su; Peter K Law; Wei Zhang; Yeanteng Lim; Kian Keong Poh; Eugene K W Sim
Journal:  J Cell Mol Med       Date:  2008-08-04       Impact factor: 5.310

8.  Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: A meta-analysis of randomised controlled trials.

Authors:  Diana Thomas Manapurathe; Smriti Murali Krishna; Brittany Dewdney; Joseph Vaughan Moxon; Erik Biros; Jonathan Golledge
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.